We recently published a list of 10 best medical actions to buy according to billionaires. In this article, we will examine where Johnson & Johnson (NYSE: JNJ) applies to other best medical actions to buy according to the billionaires.
Some experts consider that medical actions, health care and large pharmacies are immune to commercial carnage, making it a safe refuge in the midst of uncertainty caused by Trump prices. On April 8, the strategist for the health care sector of Mizuho Securities America Jared Holz appeared on CNBC’s “power lunch” to find out if speculation around the health sector being a safe refuge during market disorders are true. He also explained why health companies fail to obtain increased respect for investors, given that health care represents 20% of the American economy, which results in around 1 / 5th in the country’s entire national production.
Holz said the country’s main health and pharmaceutical care companies undoubtedly help fight health problems. However, when we examine their financial models and the way in which their activities are currently created, we have generic patent cliffs in the next 5 to 7 years at the company’s long -term corner of the company, as well as price concessions with IRA and some of the Biden administration has set up. We have also obtained a degradation of short -term prices, and between these two lies and other reverse. The models therefore never align themselves well enough for investors to have a lot of confidence, because commercial models do not lend themselves to long -term viability. These are the main reasons why the sector and stocks have been under pressure for so long.
Holz also considered that the care managed, in particular the names focused on the government, are somewhat safe because they are isolated from prices as American companies. In fact, the economic slowdown is in fact beneficial to them because they want less use and less patience through the system, this is how they generally beat figures. He said that managed care had a good day and that investors might think about having certain companies in the sector.
It is however a relative game, because there are several different variables at stake, and investors play essentially to a game of hoppes to try to switch from one zone to another, whether it is prices, prices of drugs or other public policies. He painted a similar table for stocks of medical devices more focused on the United States. These two sectors therefore present less risks compared to others, which makes them a little refuge.
In this article, we first siflé via FNB and financial media reports to compile a preliminary list of stocks. We then examined the exclusive Insider Monkey database of Billionaire Stock Holdings to select the 10 best medical actions with the most billionaire investors. These billionaires are founders or managers of some of the main hedge funds and world businesses.
Why are we interested in the stocks in which the hedge funds stacked? The reason is simple: our research has shown that we can surpass the market by imitating the main choices of stock of the best hedge funds. The strategy of our quarterly newsletter selects 14 shares with small capitalization and high capitalization each quarter and has rendered 275% since May 2014, beating its reference with 150 percentage points (See more details here).
The point of view of Jim Cramer on Johnson & Johnson (JNJ): Do the fears of disputes create a rare buying opportunity?
A baby smiling with a range of baby care products in the foreground.
Number of billionaire investors: 18
Number of hedge holders: 98
Johnson & Johnson (NYSE: JNJ) develops, manufactures and sells a range of products in the field of health care via its subsidiaries. With a main accent on products related to human well-being and health, the company operates through two segments: innovative medicine and medtech. Its innovative medicine segment includes various therapeutic areas, including infectious diseases, immunology, neuroscience, metabolic and cardiovascular diseases, pulmonary hypertension and oncology. The Medtech segment includes an developed range of medical devices and products used in cardiovascular intervention, orthopedic interventional solutions, surgery and vision fields.
Johnson & Johnson (NYSE: JNJ) has fundamental solids. He declared sales of $ 88.8 billion for the year 2024, reflecting growth of 4.3% in annual sliding. These solid results reflect the company’s high growth strategy. It has a solid assessment and generates enough cash flow through its operations to cover its high yield dividend.
On January 13, Johnson & Johnson (NYSE: JNJ) announced the acquisition of $ 14.6 billion in intracellular neurological drugs. This acquisition will allow the company to access Caplyta, an oral drug for the treatment of bipolar disorder and schizophrenia.
On April 9, Goldman Sachs analyst Asad Haider resumed the coverage with a purchase note on Johnson & Johnson (NYSE: JNJ) and set a price goal of $ 172.00. Morgan Stanley also increased the company’s price target on the company to $ 164, against $ 163, keeping an equal weight rating on actions.
Overall, Jnj rank 5th On our list of the best medical actions to buy according to the billionaires. While we recognize JNJ’s potential as an investment, our conviction lies in the conviction that certain AI actions are more promising to provide higher yields and do it within a shorter period. There is a stock of AI that has increased since the beginning of 2025, while the popular AI shares have lost around 25%. If you are looking for a more promising stock of AI than JNJ but which is negotiated within 5 times its income, consult our report on the Stock ai the cheapest.
